

# Ahmed Hamed Salem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6826988/publications.pdf>

Version: 2024-02-01

64  
papers

4,428  
citations

218381

26  
h-index

118652

62  
g-index

64  
all docs

64  
docs citations

64  
times ranked

4895  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. <i>Cancer Discovery</i> , 2016, 6, 1106-1117.	7.7	799
2	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
3	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1277-1284.	0.8	494
4	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	5.1	314
5	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
6	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017, 130, 2392-2400.	0.6	229
7	Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. <i>Clinical Therapeutics</i> , 2017, 39, 359-367.	1.1	152
8	Pharmacokinetics of Venetoclax, a Novel BCL <sub>2</sub> Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 484-492.	1.0	93
9	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	5.1	92
10	Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL <sub>2</sub> Inhibitor: Results of a Single- and Multiple-Dose Study. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1335-1343.	1.0	71
11	Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. <i>AAPS Journal</i> , 2016, 18, 1192-1202.	2.2	70
12	Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL <sub>2</sub> inhibitor, in patients with non-Hodgkin lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 846-854.	1.1	68
13	Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL <sub>2</sub> Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1355-1361.	1.0	66
14	Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 68-79.	7.7	65
15	Targeting BCL <sub>2</sub> with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 418-427.	2.0	64
16	Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. <i>Drug Metabolism and Disposition</i> , 2017, 45, 294-305.	1.7	63
17	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
18	Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 796-804.	1.0	52

#	ARTICLE	IF	CITATIONS
19	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 565-565.	0.6	46
20	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 3748-3759.	2.5	43
21	Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Clinical Pharmacokinetics</i> , 2017, 56, 515-523.	1.6	42
22	Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2017, 37, 303-309.	1.1	40
23	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019, 134, 35-35.	0.6	40
24	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	3.2	38
25	Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in HIV-Infected Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 136-143.	1.4	33
26	Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. <i>Hematological Oncology</i> , 2017, 35, 679-684.	0.8	32
27	Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. <i>Anti-Cancer Drugs</i> , 2017, 28, 911-914.	0.7	28
28	Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant <i>Staphylococcus Aureus</i> . <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 437-443.	0.9	26
29	Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2014, 53, 479-488.	1.6	25
30	Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. <i>Xenobiotica</i> , 2018, 48, 904-910.	0.5	25
31	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	0.6	24
32	Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. <i>AIDS Reviews</i> , 2015, 17, 37-46.	0.5	23
33	Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 413-421.	0.8	22
34	Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. <i>Hematological Oncology</i> , 2019, 37, 464-473.	0.8	21
35	Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 465-474.	1.1	21
36	Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 847-853.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 871-879.	0.6	20
38	Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. <i>Journal of Cancer</i> , 2017, 8, 1562-1567.	1.2	19
39	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 926-926.	0.6	17
40	Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials. <i>Hematological Oncology</i> , 2018, 36, 37-43.	0.8	16
41	Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. <i>Advances in Therapy</i> , 2018, 35, 2015-2023.	1.3	16
42	Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1091-1100.	1.6	15
43	Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1172-1175.	2.3	15
44	Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 435-440.	0.8	14
45	Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. <i>Hematological Oncology</i> , 2022, 40, 269-279.	0.8	13
46	Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. <i>Hematological Oncology</i> , 2018, 36, 547-553.	0.8	12
47	Expanding the Repertoire for "Large Small Molecules" Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 999-1008.	1.9	12
48	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. <i>Blood</i> , 2019, 134, 2649-2649.	0.6	12
49	Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1621-1634.	1.6	10
50	Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1606-1616.	1.0	10
51	A Novel Ritonavir Paediatric Powder Formulation is Bioequivalent to Ritonavir Oral Solution with a Similar Food Effect. <i>Antiviral Therapy</i> , 2015, 20, 425-432.	0.6	9
52	Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis. <i>Clinical and Translational Science</i> , 2019, 12, 625-632.	1.5	9
53	Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>International Journal of Hematology</i> , 2021, 113, 370-380.	0.7	8
54	First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 925-925.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Exposureâ€“response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. <i>Leukemia and Lymphoma</i> , 2020, 61, 56-65.	0.6	7
56	No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 400-408.	1.4	6
57	Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. <i>Clinical and Translational Science</i> , 2020, 13, 555-562.	1.5	5
58	Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 424-432.	2.3	5
59	Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 857-864.	0.6	5
60	A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on coldâ€“labeled venetoclax, from chemistry to the clinic. <i>Clinical and Translational Science</i> , 2022, 15, 244-254.	1.5	5
61	Population Pharmacokinetics and Exposureâ€“Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B-Cell Lymphoma. <i>Advances in Therapy</i> , 2022, 39, 598-618.	1.3	2
62	Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. <i>Anticancer Research</i> , 2014, 34, 2001-6.	0.5	2
63	Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. <i>Clinical Drug Investigation</i> , 2022, 42, 657-668.	1.1	1
64	Pharmacokinetics and Exposure-Response Analysis of Venetoclax+â€“Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. <i>Advances in Therapy</i> , 0, , .	1.3	0